Medical Chinese

China approves two COVID-19 antigen test kits

Weifeng — Tue, 10 Nov 2020 04:54:21 GMT

China's national medical product regulator has granted market approval to two antigen test kits that can detect COVID-19 and provide results within 20 minutes.

Developed by two biotech companies in Guangzhou and Beijing respectively, these products are the country's first approved antigen test kits for COVID-19, the National Medical Products Administration said in a statement on Thursday.

The testing tools can quickly detect positive cases when the viral load is high during the acute infection period. They can be used for early triage and rapid management of suspected patients.

As a supplement to current COVID-19 detection methods, antigen testing cannot be used alone to identify infection but should be combined with nucleic acid tests, imaging and other diagnostic information to determine the infection status, according to the statement.

It noted that further nucleic acid testing is needed for both positive and negative antigen results in suspected COVID-19 cases.

Apart from the two antigen test kits, China has so far approved 24 COVID-19 nucleic acid detection reagents and 25 antibody detection reagents. Source: Xinhua Health

Chinese, German researchers find "promising" herbal therapy for moderate COVID-19

Weifeng — Tue, 10 Nov 2020 04:49:26 GMT

In a recently-published study, Chinese and German researchers have suggested that Shufeng Jiedu capsules, a patented herbal drug composed of eight medicinal plants, might be "a promising herbal therapy for moderate COVID-19."

The scientific paper was published online on Oct. 22 by Phytomedicine, a monthly peer-reviewed medical journal. The research team included Xia Lu of Shanghai Public Health Clinical Center affiliated to Fudan University, Shi Yujing of the China Academy of Chinese Medical Sciences, Su Jie of Shanghai Tech University, and Thomas Friedemann of HanseMerkur Center for Traditional Chinese Medicine at the University Medical Center in Germany.

There is currently no confirmed cure or vaccine for COVID-19. But the use of Traditional Chinese Herbal Medicine (TCM) to combat COVID-19 got international attention because it was regularly used during the pandemic, the authors said in the study. TCM was used successfully for the treatment of SARS in 2003 and influenza A (H1N1) in 2009, they said.

Shufeng Jiedu capsules, consisting of eight medicinal plants, are recognized for the treatment of different viral respiratory infectious diseases based on their antiviral, anti-inflammatory and immunomodulatory activities against acute lung injury, the authors said.

The antiviral and anti-inflammatory properties of Shufeng Jiedu capsules were confirmed by the mouse model. The decreased inflammatory factors in the lung tissue of coronavirus-infected mice can be explained by attenuation of pro-inflammatory pathways by bioactive compounds of the capsules, they said.

Network analysis showed that 11 inflammation and immunomodulation-related pathways were influenced by bioactive compounds of the capsules, they said.

The authors had investigated data from a clinical pragmatic empirical study of patients diagnosed with COVID-19 to assess the clinical effectiveness of the capsules and to determine the optimal time to initiate treatment, according to the study.

Clinical data showed that Shufeng Jiedu capsules, added to standard antiviral therapy, significantly reduced the clinical recovery time of COVID-19 and fatigue as well as cough days, compared to standard antiviral therapy alone.

The herbal therapy was significantly more effective when used within the first eight days after the onset of COVID-19 symptoms, the authors said.

"Clinical data provided some promising evidence that the capsules might shorten the symptomatic course of COVID-19 in patients with mild and moderate symptoms. The results indicated that it is beneficial to administer the capsules immediately from the onset of the first symptoms," the authors said.

However, a large-scale randomized, double-blinded and placebo-controlled clinical trial is necessary to confirm the effect of this real-world study of Shufeng Jiedu capsules for the treatment of COVID-19 patients, they added. Source: Xinhua Health

General Medicine Year in Review 2016 -By NEJM

Weifeng — Fri, 30 Dec 2016 03:00:24 GMT

The most important medical topics of 2016, as chosen by the editors of NEJM Journal Watch General Medicine

Each year, the editors of NEJM Journal Watch General Medicine choose the year's most important thematic areas in clinical research. We try to strike a balance among relevance to primary care, recognition of landmark studies, and acknowledgment of media publicity and public awareness. Some of our stories emerge from one important study, and others come from several studies on a single topic. The order of these stories is not intended to reflect their relative importance.

Click Here To Visit Website

Ledipasvir/Sofosbuvir Tablet

Weifeng — Thu, 11 Feb 2016 10:45:58 GMT

Ledipasvir/Sofosbuvir Tablet

药品名称：Ledipasvir/Sofosbuvir Tablet

剂型规格：片剂 Ledipasvir(LDV) 90mg 、Sofosbuvir(SOF)400mg

适应症：用于基因型1慢性丙型肝炎成人感染者的治疗

注册类别：化3+6类

产品信息：

据估计，世界范围内大约有1． 7 亿人感染丙型肝炎病毒( HCV) ，占世界总人口的3%。这些感染了HCV 的患者中， 80%会发展成慢性丙肝。慢性丙肝患者中，又有20% 的患者会发展成肝硬化，有25%的可能发展成肝癌。

吉利德（Gilead）2月10日宣布，已向FDA提交了ledipasvir（LDV）+sofosbuvir（SOF）固定剂量组合片剂（LDV/SOF，90mg/400mg）新药申请（NDA），该药开发用于基因型1慢性丙型肝炎成人感染者的治疗。据估计，在美国约75%的丙肝患者为基因型1 HCV毒株感染。
2013年7月25日，FDA已授予LDV/SOF固定剂量组合药物突破性疗法认定。LDV/SOF NDA的提交，是基于3项III期研究（ION-1、ION-2、ION-3）的数据。

吉利德研发执行副总裁兼首席科学官Norbert Bischofberger博士称：“LDV/SOF NDA的提交，使我们离为所有丙型肝炎患者提供一种简单、安全、高效全口服治疗方案的目标更近了一步。根据III期研究的数据，LDV/SOF组合疗法有望在短至8周的时间里治愈基因型1 HCV患者，同时无需注射干扰素或联合利巴韦林（ribavirin）。该复方制剂预计2014年底获FDA批准上市。

Ledipasvir介绍：

代号：GS-5885

化学结构式：

化学名称（英文）：MethylN-[(2S)-1-[(6S)-6-[5-[9,9-Difluoro-7-[2-[(1S,2S,4R)-3-[(2S)-2-(methoxycarbonylamino)-3-methylbutanoyl]-3-azabicyclo[2.2.1]heptan-2-yl]-3H-benzimidazol-5-yl]fluoren-2-yl]-1H-imidazol-2-yl]-5-azaspiro[2.4]heptan-5-yl]-3-methyl-1-oxobutan-2-yl]carbamate

化学式：C49H54F2N8O6

分子量：889

CAS.NO：1256388-51-8

研发进展：待申报

合作方式：联合开发、委托开发

孟加拉国看病实录

Weifeng — Sun, 07 Feb 2016 15:38:09 GMT

目前已有超过百人随康安途孟加拉国用吉二代(Lesovir-C、Twinvir)治疗丙肝，疗效非常好，目前所有检测的患者检测结果都已经转阴。联系 Dr. Md. Kais Haider Chowdhury医生（顾问） Dhaka Medical College & Hospital (达卡医学院） Medicine Unit (内科区） Mobile: 00 88 01971951824 (手机号码) Consult Now在线顾问

招聘 NEWAYSINTERNATIONAL COMPANY LIMITED JOB IN BANGLADESH

Weifeng — Sun, 03 May 2015 17:22:59 GMT

招聘 NEWAYSINTERNATIONAL COMPANY LIMITED NEWAYSINTERNATIONAL COMPANY LIMITED（以下简称NEWAYS）是一家以港式点心为主营产品的连锁企业，并致力于港式点心在全球的推广和发展。我们秉承创新与合作的精神，合力打造一个开放分布式的动态平台型企业（即：公司在职核心管理层将持有控股公司或其子公司一定数额的股权或期权）基本待遇： 1、包食宿及签证费用 2、工作满一年提供4000元的机票补贴 3、工资及其它待遇面谈工作地点：孟加拉达卡市 ★★应聘行政岗位的人才需具备以下基本条件： 1、英语沟通能力强，熟悉电脑和办公软件的操作 2、为人诚恳，品行端正，可塑性强，能够承受工作压力 3、精通孟加拉文说写者优先录用，并作为公司孟加拉区高层主管的重点培养对象。一、行政文员多名要求：1、有行政工作者优先 2、应届毕业生亦可二、总经理助理 1名应届毕业生亦可三、经理助理多名应届毕业生亦可四、储备干部多名应届毕业生亦可 ★★应聘生产岗位的人才需具备以下基本条件：为人诚恳，品行端正，责任心强，能够承受工作压力一、点心师傅 1名要求：必须有做港式点心的丰富经验二、食品车间生产主管2名要求：有3年以上速冻食品相关加工企业的管理或研发经验. 地址：G3,Garden Road19/2(Gulmohor), Kawran Bazar,Dhaka,Bangladesh 联系电话：+88 01688189796 +8801624992229 联系QQ：572238960 邮箱：neways_hr@hotmail.com 微信：thunder0663或jackyliang2011

Medical Teachers in Chinese University

Weifeng — Sun, 05 Apr 2015 15:17:14 GMT

Job in Chinese University

Medical Teacher

Post: Lecturer
Teaching Subject: Human Anatomy (Systemic and Regional Anatomy)
Qualifications: MBBS (post graduation preferred)
Experience: Medical Teacher or Hospital Job

Call: 00 88 01534668314
Email: xue.edu.ms@asia.com

Medical Chinese Translation

Weifeng — Fri, 05 Jul 2013 07:32:51 GMT

Goal-Directed Fluid Management Based on The Pulse Oximeter-Derived Pleth Variability Index

目标指导液体管理基于脉搏血氧计派生脉搏灌注变异指数（PVI)

Reduces Lactate Levels and Improves Fluid Management.
Methods

降低乳酸水平、提高液体管理。

Methods
方法

Eighty-two patients scheduled for major abdominal surgery were randomized into 2 groups to compare
intraoperative PVI-directed fluid management (PVI group) versus standard care (control group)

定于82例腹部大手术患者随机分为2组术中PVI指示液体管理（PVI组）与标准治疗（对照组）进行比较。

After the induction of general anesthesia, the PVI group received a 500-mL crystalloid bolus and a crystalloid infusion of 2 mL • kg(-1) • h(-1).

全身麻醉诱导后，PVI组收到了500ml的晶体推注和 2ml/Kg/H 晶体液注输

Colloids of 250 mL were administered if the PVI was >13% Vasoactive drug support was given to maintain the mean arterial blood pressure above 65 mm Hg.

250mL的胶体给药, 如果PVI >13％的血管活性药物上给予支持，以维持平均动脉血压高于65mmHg

In the control group, an infusion of 500 mL of crystalloids was followed by fluid management on the basis of fluid challenges and their effects on mean arterial blood and central venous pressure.

在对照组中，500ml的晶体输液后的流体管理取决于液体的挑战和对平均动脉血和中心静脉压的影响。

Perioperative lactate levels, hemodynamic data, and postoperative complications were recorded prospectively.

围手术期乳酸水平，血流动力学数据，术后并发症前瞻性

Yemeni PM meets delegation of China's health ministry

Weifeng — Sun, 31 Mar 2013 15:17:37 GMT

Xinhua | 2013-3-31 9:05:34

Yemeni Prime Minister Mohammed Salem Basindwa on Saturday met here with a visiting delegation of China's health ministry, expressing hopes that medical and health cooperation between the two countries would be further strengthened.

During the meeting, Basindwa said China and Yemen had enjoyed five decades of medical and health cooperation, which showed China 's support to the Arab country.

The Chinese medical teams have been healing the wounded and saving lives across Yemen for 47 years, contributing to the improvement of the Yemeni people's livelihood, Basindwa said.

The Yemeni government welcomes the return of the Chinese medical personnel after they left the country due to the 2011 unrest and hopes that bilateral health cooperation will be strengthened in the future, he added.

Chinese ambassador to Yemen Chang Hua, for his part, said China sent its first medical team to Yemen in 1966 and since then, more than 3,400 doctors and nurses had been working in the country and made contribution to the Yemeni people's health improvement.
$CUT$
China values its traditional friendship with Yemen and hopes to deepen bilateral cooperation in a variety of fields, he added.

The delegation of China's health ministry arrived in Sanaa on Thursday for the resumption of the Chinese medical work in the country after a temporary departure. The Chinese medical personnel in Yemen will expand to 90 people this year and will be providing training courses along with medical services.

Chinese medicine may hold the key to treating diabetes

Weifeng — Sun, 31 Mar 2013 15:14:19 GMT

March 28, 2013 in Diabetes (Medical Xpress)—Traditional Chinese medicine could be a key weapon in the treatment of type 2 diabetes, a joint international study has found. Researchers, including The University of Queensland's Dr Sanjoy Paul and Peking University's Professor Lilong Ji from Beijing, have found that conventional drugs were significantly more effective when used alongside traditional Chinese medicine in the treatment of type 2 diabetes. The study involved a controlled clinical trial of 800 type 2 diabetic adults, comparing anti-diabetic drug Glibenclamide as a stand-alone treatment and treatment with Glibenclamide in conjunction with traditional Chinese medicine. Dr Paul, who is Director of the Queensland Clinical Trials and Biostatistics Centre in UQ's School of Population Health, said results showed patients treated with traditional Chinese medicine were more than a third less likely to experience hypoglycaemia – dangerously low levels of blood sugar – than those treated with Glibenclamide only. "They were also less likely to experience other symptoms of diabetes, including fatigue, hunger and palpitation," Dr Paul said. "Traditional Chinese medicine has long been used to treat diabetes in China and around the world but until now there has been a lack of evidence regarding its safety and efficacy. "This absence of scientific understanding has caused scepticism and criticism about traditional Chinese medicine." Dr Paul said more studies were needed to interpret just how traditional Chinese medicine worked to reduce hypoglycaemia, but the study results highlighted its potential to reduce the treatment gap in developing countries where diabetes was at epidemic proportions. "A vast majority of people in developing countries depend on herbal medicine for basic health care," Dr Paul said. "The findings of this study may improve the safe delivery of effective health care to people who may otherwise be unable to access treatment." The study is the largest scientifically designed clinical trial evaluating the safety and efficacy of traditional Chinese medicine on glycaemic control in patients with type 2 diabetes. The paper is published in PLOS One. More information: www.plosone.org/ar… pone.0056703 Journal reference: PLoS ONE search and more info website Provided by University of Queensland Read more at: http://medicalxpress.com/news/2013-03-chinese-medicine-key-diabetes.html#jCp